AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37556913 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 894999 (Schedule B: 1.5, 2.0, and 2.5 mg, Days 1-15/21-d cycle)
Number of subjects: 77
Study 37556913 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 894999 (Schedule C: loading dose 5.0, 6.0, or 7.0 mg on Day 1 followed by maintenance dose 2.5, 3.0, or 3.5 mg, Days 2-7 and 15-21/28-d cycle)
Number of subjects: 77
Study 37557957 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched breakfast
Number of subjects: 12
Study 37557957 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich breakfast
Number of subjects: 12
Study 37557957 — intervention group
Group type: COMPARATOR
Intervention: Extended morning fasting
Number of subjects: 12
Study 37558060 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher gestational vitamin D exposure
Number of subjects: 672
Study 37558144 — intervention group
Group type: EXPERIMENTAL
Intervention: Heli-FX EndoAnchor System with Endurant stent graft
Number of subjects: 70
Study 37558348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrethroid (PY)-LLIN
Number of subjects: 39207
Study 37558348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyriproxyfen PY-LLIN
Number of subjects: 39207
Study 37558348 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide PY-LLIN
Number of subjects: 39207
Study 37558348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorfenapyr PY-LLIN
Number of subjects: 39207
Study 37558369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical beating-heart septal myectomy (TA-BSM)
Number of subjects: 47
Study 37558371 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 101
Study 37558400 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modulating therapy (DMT)
Number of subjects: 1645
Study 37558400 — intervention group
Group type: COMPARATOR
Intervention: Interferons
Number of subjects: 1645
Study 37558400 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 1645
Study 37558445 — intervention group
Group type: EXPERIMENTAL
Intervention: AndroidAPS (Do-it-yourself artificial pancreas system)
Number of subjects: 24
Study 37558445 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump
Number of subjects: 24
Study 37558445 — intervention group
Group type: EXPERIMENTAL
Intervention: AndroidAPS
Number of subjects: 24
Study 37558604 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive coronary artery disease (oCAD)
Number of subjects: 1836
Study 37558604 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 1836
Study 37558604 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD)
Number of subjects: 1836
Study 37558604 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal invasive measurements
Number of subjects: 1836
Study 37558604 — intervention group
Group type: EXPERIMENTAL
Intervention: Target vessel failure
Number of subjects: 1836
Study 37558912 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus oral antidepressant (AD)
Number of subjects: 96
Study 37558912 — intervention group
Group type: COMPARATOR
Intervention: AD plus placebo nasal spray (PBO)
Number of subjects: 96
Study 37558990 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-Care + MGVA (multidisciplinary group videoconferencing approach)
Number of subjects: 18
Study 37558990 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care alone
Number of subjects: 18
Study 37559004 — intervention group
Group type: EXPERIMENTAL
Intervention: WEBAPPAC web-application support
Number of subjects: 438
Study 37559004 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 438
Study 37559023 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adequate haemodialysis with a dialysate potassium concentration of 2.0 mmol/L
Number of subjects: 600
Study 37559023 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adequate haemodialysis
Number of subjects: 600
Study 37559026 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 265
Study 37559050 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg per day for 21 days every 28 days
Number of subjects: 15
Study 37559050 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 15
Study 37559069 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 (assigned subgoal)
Number of subjects: 628
Study 37559069 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 (participatory subgoal)
Number of subjects: 628
Study 37559069 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (fixed goal)
Number of subjects: 628
Study 37559069 — intervention group
Group type: COMPARATOR
Intervention: Control (usual standard of care)
Number of subjects: 628
Study 37559069 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 628
Study 37559112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (2 sessions, one per week, plus usual rehabilitation program)
Number of subjects: 32
Study 37559112 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation program only
Number of subjects: 32
Study 37559142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine
Number of subjects: 100
Study 37559158 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARThealth Pregnancy intervention (education program, app for screening, monitoring dashboard, supply chain monitoring, stakeholder engagement)
Number of subjects: 30
Study 37559158 — intervention group
Group type: COMPARATOR
Intervention: Usual care with additional health worker education (control group)
Number of subjects: 30
Study 37559163 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) with serum NSE measured at 48 hours after return of spontaneous circulation.
Number of subjects: 623
Study 37559163 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE cutoff values for predicting poor outcome with FPR < 1% in non-shockable group.
Number of subjects: 623
Study 37559163 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE cutoff values for predicting poor outcome with FPR < 1% in shockable group.
Number of subjects: 623
Study 37559163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic performance of NSE assessed by area under the receiver operating characteristic curve.
Number of subjects: 623
Study 37559343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim
Number of subjects: 27
Study 37559343 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 27
Study 37559349 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intra venous anesthesia (TIVA)
Number of subjects: 0
Study 37559349 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with volatile anesthetics (VOL)
Number of subjects: 0
Study 37559435 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic 7T images generated by a generative adversarial network (SynGAN) from 3T images.
Number of subjects: 122
Study 37559435 — intervention group
Group type: COMPARATOR
Intervention: Acquired 7T images.
Number of subjects: 122
Study 37559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine therapy (n = 12)
Number of subjects: 28
Study 37559530 — intervention group
Group type: COMPARATOR
Intervention: No caffeine therapy (n = 16)
Number of subjects: 28
Study 37559718 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 85
Study 37559718 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab + Lenalidomide
Number of subjects: 85
Study 37559718 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Daratumumab + Pomalidomide
Number of subjects: 85
Study 37559753 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg lufotrelvir (SAD)
Number of subjects: 30
Study 37559753 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg lufotrelvir (SAD)
Number of subjects: 30
Study 37559753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAD)
Number of subjects: 30
Study 37559753 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg lufotrelvir (MAD)
Number of subjects: 30
Study 37559753 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg lufotrelvir (MAD)
Number of subjects: 30
Study 37559753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MAD)
Number of subjects: 30
Study 37559752 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral Adiposity Index (VAI)
Number of subjects: 45
Study 37559825 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 100
Study 37559825 — intervention group
Group type: COMPARATOR
Intervention: alglucosidase alfa
Number of subjects: 100
Study 37560085 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) with high titer neutralizing activity
Number of subjects: 702
Study 37560085 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 702
Study 37560089 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-based intervention
Number of subjects: 0
Study 37560161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (BID)
Number of subjects: 1139
Study 37560161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1139
Study 37560175 — intervention group
Group type: EXPERIMENTAL
Intervention: eIPOS (electronic Integrated Palliative Care Outcome Scale)
Number of subjects: 0
Study 37560259 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with neoadjuvant chemoradiotherapy (NCRT)
Number of subjects: 44
Study 37560461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 37560461 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 37560461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37560749 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-producing fruit and vegetables (experimental group)
Number of subjects: 40
Study 37560749 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (control group)
Number of subjects: 40
Study 37560813 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with dose reduction in patients ≤55 years old after achieving complete metabolic response (CMR)
Number of subjects: 107
Study 37560813 — intervention group
Group type: COMPARATOR
Intervention: Immunochemotherapy with standard dose (BURKIMAB08 trial)
Number of subjects: 107
Study 37560813 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (BURKIMAB14 trial)
Number of subjects: 107
Study 37560967 — intervention group
Group type: EXPERIMENTAL
Intervention: ORBCEL-M (80×10^6 cells)
Number of subjects: 16
Study 37560967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 37560967 — intervention group
Group type: EXPERIMENTAL
Intervention: ORBCEL-M
Number of subjects: 16
Study 37561058 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF 25 mg once daily
Number of subjects: 1298
Study 37561058 — intervention group
Group type: COMPARATOR
Intervention: TDF 300 mg once daily (followed by TAF after 2 or 3 years)
Number of subjects: 1298
Study 37561087 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated watermelon rind (WR)
Number of subjects: 12
Study 37561087 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated watermelon rind with beetroot (WR + B)
Number of subjects: 12
Study 37561087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 37561246 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial GP ablation with pulsed field (PF) during CABG
Number of subjects: 24
Study 37561246 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring post-procedure
Number of subjects: 24
Study 37561246 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative AF observation
Number of subjects: 24
Study 37561246 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) assessment
Number of subjects: 24
Study 37561249 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy (OR) with a total dose of 20 Gy, divided into 10 sessions of 2 Gy each, with concomitant oral intake of low-dose glucocorticoids.
Number of subjects: 26
Study 37561269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 16
Study 37561269 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 16
Study 37561355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task program (balance and cognitive), 3 days per week for 8 weeks
Number of subjects: 30
Study 37561355 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 30
Study 37561451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab without chemotherapy (group A)
Number of subjects: 210
Study 37561451 — intervention group
Group type: COMPARATOR
Intervention: Pertuzumab plus trastuzumab with chemotherapy (group B)
Number of subjects: 210
Study 37561461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-corrected AKI diagnosis
Number of subjects: 923
Study 37561461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-corrected AKI
Number of subjects: 923
Study 37561558 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual meal
Number of subjects: 20
Study 37561558 — intervention group
Group type: COMPARATOR
Intervention: Real meal
Number of subjects: 20
Study 37561571 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Girlfriend program
Number of subjects: 10000
Study 37561571 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (1-page information sheet on condom use)
Number of subjects: 10000
Study 37561579 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 19
Study 37561579 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 19
Study 37561748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap and COVID-19 vaccination rates
Number of subjects: 0
Study 37561748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes screening
Number of subjects: 0
Study 37561748 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of post-partum hospital stay
Number of subjects: 0
Study 37561748 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of depression, anxiety, and adjustment disorder
Number of subjects: 0
Study 37561967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 77
Study 37562004 — intervention group
Group type: EXPERIMENTAL
Intervention: OAsIs combination therapy (targeted therapies against CD20, BCL2, and Bruton tyrosine kinase)
Number of subjects: 0
Study 37562004 — intervention group
Group type: EXPERIMENTAL
Intervention: MALT1 protease inhibition
Number of subjects: 0
Study 37562004 — intervention group
Group type: EXPERIMENTAL
Intervention: CARD11 gain of function
Number of subjects: 0
Study 37562004 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-gene resistance signature
Number of subjects: 0
Study 37562003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 391
Study 37562051 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant ACE2-P18F3
Number of subjects: 0
Study 37562063 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin/relebactam (maximum dose of 15 mg/kg imipenem and 15 mg/kg cilastatin, 7.5 mg/kg relebactam)
Number of subjects: 46
Study 37562095 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg BID or 1500 mg BID) combined with platinum-based chemoradiation
Number of subjects: 25
Study 37562095 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin compliance ≥70%
Number of subjects: 25
Study 37562095 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 25
Study 37562120 — intervention group
Group type: EXPERIMENTAL
Intervention: TOKA personalised HTO system
Number of subjects: 25
Study 37562195 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-low (IHC 1+ or IHC 2+/ISH-)
Number of subjects: 789
Study 37562641 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1026706 100 mg bid
Number of subjects: 57
Study 37562641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 37562757 — intervention group
Group type: EXPERIMENTAL
Intervention: Surefil one™ Self-Adhesive bulk-fill resin composite
Number of subjects: 83
Study 37562757 — intervention group
Group type: COMPARATOR
Intervention: Filtek™ Bulk-Fill posterior composites
Number of subjects: 83
Study 37562791 — intervention group
Group type: EXPERIMENTAL
Intervention: nCLE imaging of granulomas
Number of subjects: 25
Study 37562791 — intervention group
Group type: EXPERIMENTAL
Intervention: nCLE imaging of lung nodules
Number of subjects: 25
Study 37562791 — intervention group
Group type: EXPERIMENTAL
Intervention: nCLE imaging of lymph nodes
Number of subjects: 25
Study 37562934 — intervention group
Group type: EXPERIMENTAL
Intervention: Codesigned complex intervention to prevent pressure ulcers, malnutrition, poor oral health and falls
Number of subjects: 16
Study 37562934 — intervention group
Group type: EXPERIMENTAL
Intervention: Codesigned complex intervention
Number of subjects: 16
Study 37563004 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliapixant 125 mg twice daily
Number of subjects: 202
Study 37563004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 37563240 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab combined with mFOLFOX6 chemotherapy
Number of subjects: 57
Study 37563313 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic thermal ablation with CT during hepatic arteriography (CTHA) imaging and computer-based software assessment of ablation margins
Number of subjects: 50
Study 37563313 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic thermal ablation
Number of subjects: 50
Study 37563553 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-based movement intervention (activPAL and StepWatch)
Number of subjects: 50
Study 37563553 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 50
Study 37563568 — intervention group
Group type: EXPERIMENTAL
Intervention: hrBMP4 (0.5 to 18 mg)
Number of subjects: 15
Study 37563595 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS system to support a culturally-adapted Diabetes Prevention Program (DPP)
Number of subjects: 0
Study 37563595 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS system
Number of subjects: 0
Study 37563608 — intervention group
Group type: EXPERIMENTAL
Intervention: Esperanza extract (Petiveria alliacea)
Number of subjects: 0
Study 37563608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37563608 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 0
Study 37563665 — intervention group
Group type: EXPERIMENTAL
Intervention: TreC Diabete platform as part of their personalised care plan
Number of subjects: 0
Study 37563665 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 37563914 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine with add-on Alpha-Lipoic Acid (ALA)
Number of subjects: 60
Study 37564370 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic SCiP™ therapy for 8 weeks (G2)
Number of subjects: 60
Study 37564370 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 8 weeks (G1)
Number of subjects: 60
Study 37564370 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic SCiP™ therapy for another 8 weeks (G2)
Number of subjects: 60
Study 37564370 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation followed by therapeutic SCiP™ therapy for 8 weeks (G1)
Number of subjects: 60
Study 37564370 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based neurorehabilitation therapy (ABNT) 2 days/week for both groups
Number of subjects: 60
Study 37564370 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale (secondary outcome)
Number of subjects: 60
Study 37564370 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency and severity of adverse events
Number of subjects: 60
Study 37564743 — intervention group
Group type: EXPERIMENTAL
Intervention: RBL (Live-Jslm)
Number of subjects: 185
Study 37564743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 37564986 — intervention group
Group type: EXPERIMENTAL
Intervention: N11005 (300 IU, p.o.)
Number of subjects: 12
Study 37564986 — intervention group
Group type: COMPARATOR
Intervention: Novolin R (0.1 IU/Kg, i.h.)
Number of subjects: 12
Study 37565238 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function-Preschool (BRIEF-P) version
Number of subjects: 357
Study 37565238 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy reports of EF impairment
Number of subjects: 357
Study 37565238 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental socioeconomic level
Number of subjects: 357
Study 37565290 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37565307 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (antiplatelet agent)
Number of subjects: 11571
Study 37565307 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (antihypertensive agent)
Number of subjects: 11571
Study 37565307 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (antihypertensive agent)
Number of subjects: 11571
Study 37565307 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (anticoagulant agent)
Number of subjects: 11571
Study 37565307 — intervention group
Group type: COMPARATOR
Intervention: Lipid-lowering agents (atorvastatin, fluvastatin, lovastatin, pravastatin, probucol, rosuvastatin)
Number of subjects: 11571
Study 37565393 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-related blood sampling (1.6 ± 0.6 mL/kg)
Number of subjects: 193
Study 37565393 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical blood sampling (8.1 ± 5.1 mL/kg)
Number of subjects: 193
Study 37565541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg oral dose
Number of subjects: 8
Study 37565934 — intervention group
Group type: COMPARATOR
Intervention: Multifaceted implementation intervention
Number of subjects: 42489